Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentation Additionally, new data and updates from AbbVie's telisotuzumab adizutecan (Temab-A) and ABBV-706 programs across NSCLC and small cell lung cancer (SCLC) to be shared Research reflects AbbVie's strategy aimed at building a lung cancer pipeline spanning next-generation immunotherapies, targeted antibody- drug conjugates (ADCs) and the potential for novel combination approaches NORTH CHICAGO, Ill., Aug. 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Dividend investors have had plenty to cheer in 2026. Pfizer (NYSE:PFE | PFE Price Prediction) is up 19.3% year to date, Chevron (NYSE:CVX) has surged 38.76%, and AbbVie (NYSE:ABBV) has added 19.16%.

A mechanical yield screen is quietly outpacing the S&P 500 this year by excluding most of the AI complex before a single share is purchased, and the valuation gap it creates raises a question worth answering before the rotation reverses.

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.

D.A. Davidson and CO. reduced its stake in AbbVie Inc. (NYSE: ABBV) by 10.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 243,700 shares of the company's stock after selling 28,907 shares during the quarter. D.A. Davidson and

Benjamin Edwards Inc. lessened its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 3.4% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 327,322 shares of the company's stock after selling 11,582 shares during the quarter. AbbVie makes up 0.8% of

EverSource Wealth Advisors LLC decreased its stake in AbbVie Inc. (NYSE: ABBV) by 17.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,434 shares of the company's stock after selling 2,393 shares during the quarter. EverSource

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

Since its 2016 launch, hundreds of exceptional students pursuing higher education have received the scholarship Now a renewable award, students may earn the AbbVie Immunology Scholarship for up to four years Recipients live with conditions such as atopic dermatitis, psoriasis, Crohn's disease, ulcerative colitis and juvenile idiopathic arthritis NORTH CHICAGO, Ill., Aug. 18, 2026 /PRNewswire/ --  AbbVie (NYSE: ABBV) today announced 34 students living with inflammatory conditions across dermatology, gastroenterology and rheumatology will receive the 2026 AbbVie Immunology Scholarship, as the program marks its 10th year.

Johnson Investment Counsel Inc. cut its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 1.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 155,264 shares of the company's stock after selling 2,946 shares during the quarter. Johnson Investment Counsel Inc.'s